ST Engineering iDirect and solutions by stc Strengthen Strategic Partnership to Advance Satcom Services in Saudi Arabia
Expanded satellite network collaboration enhances connectivity solutions and supports Vision 2030's digital transformation ambitions.
HERNDON, Va., June 19, 2025 /CNW/ -- ST Engineering iDirect, a global leader in satellite communications, today announced a strategic partnership with solutions by stc to deliver advanced satellite communication services across the Kingdom of Saudi Arabia. This collaboration directly supports Saudi Arabia's Vision 2030, enhancing the nation's digital transformation ambitions by utilizing local satellite assets to provide flexible, resilient, and secure connectivity across diverse sectors and applications.
Under this partnership, solutions by stc has significantly expanded its ST Engineering iDirect ground network by incorporating advanced products designed for both fixed and mobile applications. These infrastructure upgrades enable solutions by stc to offer reliable and scalable satellite connectivity to a wide range of customers, including government entities, enterprises, and cellular network operators. ST Engineering iDirect's software-upgradable technology ensures the network evolves alongside the Kingdom's rapidly growing connectivity demands, reinforcing its strategic alignment with the nation's digital growth.
Saudi Arabia's digital transformation is advancing at a dynamic pace projected to grow from US$55.15 billion in 2025 to US$90.25 billion by 2030. This partnership strategically positions solutions by stc to meet the demand for high-bandwidth, cost-effective digital communication services while supporting the Kingdom's ambitious growth initiatives.
"This collaboration with solutions by stc is a testament to our shared vision of delivering advanced connectivity solutions that empower digital transformation across the Kingdom," said Don Claussen, CEO at ST Engineering iDirect. "We are honored to contribute to Saudi Arabia's efforts in building a robust, future-ready connectivity framework."
ST Engineering iDirect, a subsidiary of ST Engineering, is a global leader in satellite communications (satcom) providing technology and solutions that enable its customers to expand their business, differentiate their services and optimize their satcom networks. With over 40 years of delivering innovation focused on solving satellite's most critical economic and technology challenges we are committed to shaping the future of how the world connects. The product portfolio, branded iDirect, represents the highest standards in performance, efficiency and reliability, making it possible for its customers to deliver the best satcom connectivity experience anywhere in the world. ST Engineering iDirect is a leader in key industries including mobility, broadcast and military/government. In 2007, iDirect Government was formed to better serve the U.S. government and defense communities. For more information visit www.idirect.net.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
13 minutes ago
- Cision Canada
FÉRIQUE Fund Management expands its fund family with the launch of the FÉRIQUE 100% Equity Portfolio Français
MONTREAL, June 20, 2025 /CNW/ - FÉRIQUE Fund Management is pleased to announce the launch of the FÉRIQUE 100% Equity Portfolio, a new investment solution geared to long-term growth. This mutual fund will be available from June 26, 2025, to provide full exposure to global equity markets. The new fund responds to the growing demand for diversified investment solutions with full exposure to the equity markets. The FÉRIQUE 100% Equity Portfolio has a fund-of-funds structure, offering sound strategic diversification by region, sector and management style. "The portfolio has been designed and optimized to provide a simple and efficient gateway to the global equity markets," explained Francis Fortin, Vice President, Investments, at FÉRIQUE Fund Management. "It meets the needs of investors who want to take advantage of the return potential of the equity markets, while benefitting from rigorous management." The fund will be managed by FÉRIQUE Fund Management. In addition to offering regular rebalancing, the portfolio will have some of the industry's most competitive management expense ratios in its category. The new fund, which is available exclusively to engineering professionals, their families and their businesses, expands the investment options available to them, offering a solution geared to long-term growth. "Adding this fund enhances our offering so that we can better meet the varied profiles of investors who wish to invest in the FÉRIQUE Funds," Mr. Fortin added. "We're proud to continue developing solutions that support the financial independence of engineering professionals in Quebec." Founded in 1999, FÉRIQUE Fund Management ( is the manager of the FÉRIQUE Funds. It is the only not-for-profit mutual fund company in Canada dedicated solely to serving the interests of engineering professionals and their families. The company offers 18 mutual funds, including 6 portfolios representing the different asset classes required for healthy diversification. Fund management is entrusted to reputable external firms mandated by FÉRIQUE Fund Management according to their respective specialties. FÉRIQUE Funds total nearly $4.5 billion and has more than 24,000 participants as of March 31, 2025.
Cision Canada
an hour ago
- Cision Canada
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
VANCOUVER, BC, June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Immuneering Corporation (NASDAQ: IMRX), GRAIL, Inc. (NASDAQ: GRAL), Intensity Therapeutics, Inc. (NASDAQ: INTS), and Relay Therapeutics, Inc. (NASDAQ: RLAY). The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution. Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration. Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types. In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation. Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners. With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus. In other recent industry developments and happenings in the market include: Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey." The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors. GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults. "We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman, MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward." The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation. Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result." MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint. Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. "We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year." Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
an hour ago
- Cision Canada
Reklaim Expands 'Protect' to Include California Opt-Outs, Ad Tech Removal, and Family Protection
Subscribers' data is now automatically removed from California-registered data brokers, as well as enterprise and DSP platforms TORONTO, June 20, 2025 /CNW/ - Reklaim Ltd. (TSXV: MYID) (OTC: MYIDF) ("Reklaim" or the "Company"), a leader in consumer data privacy and compliant data monetization, today announced a significant update to Reklaim Protect, its privacy subscription service that helps users shrink their digital footprint. With this latest release, Reklaim Protect now automatically removes subscriber data from companies listed in California's official data broker registry, as well as enterprise data platforms and demand-side platforms (DSP s) used in digital advertising. These new capabilities further strengthen Reklaim's position as a privacy-first alternative for consumers who want to opt out of the data economy and reduce the availability of their information for sale, targeting, or unauthorized use. "Removing your data from these platforms is about cutting off the source," said Neil Sweeney, Founder and CEO of Reklaim. "Brokers, fraudsters, and bad actors all rely on the same data supply to power their models. If you don't proactively reduce your footprint, your information remains exposed and in circulation. By integrating the California registry, we're cutting subscribers off from one of the largest data pipelines in the world." Key Features of Reklaim Protect (V2) California Data Broker Registry Opt-Out Reklaim subscribers' data is now automatically removed from data brokers listed in California's official registry, the largest of its kind in the world, with a single digital signature inside the Reklaim app. This step leverages state privacy laws to disconnect consumers from some of the most active and persistent data sellers in the U.S. View the official registry ➝ Enterprise & DSP Data Removal Reklaim now facilitates opt-outs from enterprise data platforms and demand-side platforms (DSPs) used by advertisers to profile and target consumers, helping reduce unwanted surveillance and behavioural tracking. Family-Wide Monitoring Protect Subscribers, who are also members of Reklaim Rewards, can also monitor up to 10 verified email addresses for dark web breaches, extending protection to family members and close contacts. These enhancements build on the original features of Reklaim Protect, which include: Reklaim Protect is available to Reklaim subscribers in Canada and the United States, offering a 14-day free trial and ongoing access for just $1/month or $10/year. The service is fully integrated into the Reklaim mobile and web app experience.
